Showing results (11-20 of 37) with videos related to
Sort By:
Pageof 4
BMC Cancer|May 26, 2026
Whole genome sequencing in oesophageal adenocarcinoma unmasks potential precision therapiesSowmya Sharma, Ho Yi Wong, Rebecca L Johnston, et al.Plos One|June 21, 2014
Assessment of PALB2 as a candidate melanoma susceptibility geneLauren G Aoude, Mai Xu, Zhen Zhen Zhao, et al.Frontiers in Immunology|November 15, 2023
The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy - results from the AGITG DOCTOR trial and the cancer evolution biobankJames M Lonie, Sandra Brosda, Vanessa F Bonazzi, et al.Journal of Medical Genetics|May 9, 2024
POT1 and multiple primary melanomas: the dermatological phenotypeEllie J Maas, Emily DeBortoli, Vaishnavi Nathan, et al.Familial Cancer|August 8, 2015
POLE mutations in families predisposed to cutaneous melanomaLauren G Aoude, Ellen Heitzer, Peter Johansson, et al.Genome Medicine|July 17, 2024
Spatial intra-tumour heterogeneity and treatment-induced genomic evolution in oesophageal adenocarcinoma: implications for prognosis and therapySandra Brosda, Lauren G Aoude, Vanessa F Bonazzi, et al.The Journal of Molecular Diagnostics : JMD|August 6, 2023
Circulating Tumor DNA: A Promising Biomarker for Predicting Recurrence in Patients with BRAF-Negative MelanomaLauren G Aoude, Sandra Brosda, Jessica Ng, et al.Scientific Reports|October 20, 2020
Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patientsLauren G Aoude, Vanessa F Bonazzi, Sandra Brosda, et al.Asia-Pacific Journal of Clinical Oncology|July 7, 2023
C-reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patientsVanessa F Bonazzi, Lauren G Aoude, Sandra Brosda, et al.Molecular Cancer Therapeutics|March 3, 2012
A high-throughput panel for identifying clinically relevant mutation profiles in melanomaKen Dutton-Regester, Darryl Irwin, Priscilla Hunt, et al.Pageof 4